Treatment options could include therapies inhibiting the IL-23/IL-17 axis or antibodies targeting the Janus kinase/Signal Transducer and Activator of Transcription (Jak/Stat) pathway, representing a new direction in the treatment of PPMS (41). Here, SOAT1 is linked to primary progressive multiple sclerosis.